BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback